Company Overview and News

 
Final Results

2017-05-03 londonstockexchange
Prospex Oil and Gas Plc / Index: AIM / Epic: PXOG / Sector: Oil and Gas

 
Non-Executive Director Appointment

2017-04-13 londonstockexchange
Blenheim Natural Resources Plc (the "Company" or "Blenheim") is pleased to announce the appointment of Mr Christian Schaffalitzky as a Non-Executive Director of the Company with immediate effect.

 
Appointment of new Director

2016-11-15 londonstockexchange
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").

 
Final Results

2016-06-10 londonstockexchange
2015 and the first part of 2016 was a transformational period for the Company. In April 2015, Prospex became an AIM investing company. Since April 2015, the new management team has reviewed over 20 projects and over the period the Company made several investments. The most significant investment to date is the acquisition of 49% of the shares of Hutton Poland which in turn holds the Kolo license.

 
Appendix 3B

2016-02-08 asx.com.au

 
Quarterly Activities Report

2016-01-29 asx.com.au

 
Quarterly Cashflow Report

2016-01-29 asx.com.au

 
5 Dividend Paying Companies With No, Or Very Little Debt (Part 1)

2016-01-04 seekingalpha
We will take a look at five companies that pay a dividend and currently have little or no debt on their balance sheets.By looking at the debt of a company we can locate some very financially healthy b

 
Results of Meeting

2015-11-12 asx.com.au

 
Quarterly Activities Report

2015-10-30 asx.com.au

 
Quarterly Cashflow Report

2015-10-30 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...